Brokerages Set United Therapeutics Co. (NASDAQ:UTHR) Price Target at $388.25

Shares of United Therapeutics Co. (NASDAQ:UTHR) have earned an average rating of “Moderate Buy” from the twelve research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $388.25.

Several research analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. UBS Group boosted their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Finally, StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th.

Insider Activity at United Therapeutics

In other United Therapeutics news, Director Nilda Mesa sold 255 shares of the company’s stock in a transaction on Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the completion of the transaction, the director now owns 5,528 shares in the company, valued at approximately $1,966,696.56. This represents a 4.41 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $348.06, for a total transaction of $3,480,600.00. Following the transaction, the chief operating officer now owns 2,577 shares of the company’s stock, valued at approximately $896,950.62. The trade was a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 90,255 shares of company stock worth $32,614,521 in the last 90 days. 11.90% of the stock is owned by insiders.

Hedge Funds Weigh In On United Therapeutics

Large investors have recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC grew its stake in shares of United Therapeutics by 15.8% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,643 shares of the biotechnology company’s stock worth $1,991,000 after purchasing an additional 769 shares during the period. NorthCrest Asset Manangement LLC grew its stake in shares of United Therapeutics by 1.5% during the 4th quarter. NorthCrest Asset Manangement LLC now owns 5,598 shares of the biotechnology company’s stock worth $1,975,000 after purchasing an additional 84 shares during the period. Lansforsakringar Fondforvaltning AB publ acquired a new position in shares of United Therapeutics during the 4th quarter worth $4,778,000. Siemens Fonds Invest GmbH acquired a new position in shares of United Therapeutics during the 4th quarter worth $162,000. Finally, Park Square Financial Group LLC acquired a new position in shares of United Therapeutics during the 4th quarter worth $217,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $318.85 on Friday. The stock has a market capitalization of $14.32 billion, a P/E ratio of 14.00, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64. The company has a 50 day moving average price of $347.20 and a 200 day moving average price of $357.65. United Therapeutics has a fifty-two week low of $221.53 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. The firm had revenue of $735.90 million during the quarter, compared to analysts’ expectations of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter in the previous year, the business posted $4.36 earnings per share. On average, research analysts forecast that United Therapeutics will post 24.48 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.